EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies

Corrado Girmenia iD, Tiziana Lazzarotto, Massimo Martino, Francesca Bonifazi, Fausto Baldanti, Pierangelo Clerici, Franco Citterio iD, Luciano De Carlis, Giovanni Barosi, Paolo Antonio Grossi

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70255 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation, 2025. Written by Corrado Girmenia and 9 co-authors. Institution: Department of Hematology, Oncology and Dermatology, AOU Policlinico Umberto I, Sapienza University of Rome, Roma, Italy. Major MEDLINE topics: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Antiviral Agents, Organ Transplantation. Cited 12 times so far (Crossref); 105 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

New options for prevention and therapy of cytomegalovirus (CMV) infection and new tests for antiviral immune reconstitution are leading to increased complexity in the management of CMV after allogeneic hematopoietic stem cell (allo‐HSCT) and solid organ transplantation (SOT) recipients. To inform the optimal care of these patients, under the auspices of the Italian GITMO, SITO, SIMIT, and AMCLI transplant, infectious, and clinical microbiology societies, we updated the guidelines published in 2019. New recommendations were produced using a consensus‐building methodology after a comprehensive review of articles released from 2019 to 2025 (March). Five domains and 31 key questions were selected through a series of questionnaires using a Delphi process. The recommendations on CMV management in transplant recipients were related to diagnostics, prevention, and treatment. Key recommendations include: in both allo‐HSCT and SOT, donor and recipient should be evaluated for anti‐CMV serological status before transplant for risk stratification; monitoring of CMV infection after transplant should be performed by assaying CMV DNAemia with real time PCR; CMV‐specific cell mediated immunity should be monitored after transplantation in allo‐HSCT and SOT; in CMV seropositive adult allo‐HSCT recipients with negative CMV DNAemia, letermovir prophylaxis is recommended; there is no mandatory indication to universal prophylaxis in SOT recipients; preemptive antiviral therapy is recommended in patients with clinically significant CMV infection (CS‐CMV‐i); in patients with resistant or refractory CMV infection or disease after first‐line antiviral therapy, oral maribavir is recommended as second line antiviral therapy. In conclusion, these recommendations aim to guide clinical practice and improve outcomes in this high‐risk population.

Subjects

MeSH terms (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationAntiviral AgentsOrgan TransplantationCytomegalovirusPractice Guidelines as TopicHumansItalySocieties, MedicalDisease ManagementPrognosisTransplantation, Homologous

Author keywords

cytomegalovirusdiagnosishematopoietic stem cell transplantpreemptive therapyprophylaxissolid organ transplant

Substances

Antiviral Agents

Authors and institutions

  • Department of Hematology, Oncology and Dermatology, AOU Policlinico Umberto I, Sapienza University of Rome, Roma, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Hematology and Stem Cell Transplantation and Cellular Rerapies Unit (CTMO), Stem Cell Transplant Program CIC 587, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli"…
  • Hematopoietic Stem Cell Transplant Program, IRCSS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
  • Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

ORCID profiles: Corrado Girmenia, Franco Citterio

Cite

APA

Girmenia, C., Lazzarotto, T., Martino, M., Bonifazi, F., Baldanti, F., Clerici, P., Citterio, F., De Carlis, L., Barosi, G., & Grossi, P. A. (2025). Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies. Clinical Transplantation. https://doi.org/10.1111/ctr.70255

Vancouver

Girmenia C, Lazzarotto T, Martino M, Bonifazi F, Baldanti F, Clerici P, et al. Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies. Clinical Transplantation. 2025. doi:10.1111/ctr.70255

BibTeX
@article{Girmenia2025,
  author = {Girmenia, Corrado and Lazzarotto, Tiziana and Martino, Massimo and Bonifazi, Francesca and Baldanti, Fausto and Clerici, Pierangelo and Citterio, Franco and De Carlis, Luciano and Barosi, Giovanni and Grossi, Paolo Antonio},
  title = {Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70255}
}
Start for free →